Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Becton, Dickinson and Company

Initial Statement of Beneficial Ownership

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Michael Feld	Executive VP & President of the Life Sciences Segment Show All	Automatic Disposition (Automatic Disposition)	-75.0	-0.000026%	-0.5%	16.6K	193.4 - 193.4	-14.5K	02 Dec 2025	01 Dec 2025 - 01 Dec 2025
Jacqueline Wright	Independent Director Show All	Other Acquisition (Other Acquisition)	180.0	—	—	180.0	—	—	02 Dec 2025	01 Dec 2025 - 01 Dec 2025
Robert Luther Huffines	Independent Director Show All	Other Acquisition (Other Acquisition)	180.0	—	—	180.0	—	—	02 Dec 2025	01 Dec 2025 - 01 Dec 2025
Pavan Kumar Mocherla	Executive VP & President of Greater Asia Show All	Other Acquisition (Other Acquisition)	2.9K	0.001021%	102.4%	5.8K	—	—	01 Dec 2025	26 Nov 2025 - 26 Nov 2025
David Shan	Executive VP & Chief Integrated Supply Chain Officer Show All	Other Acquisition (Other Acquisition)	4.5K	0.001586%	102.0%	9.0K	—	—	01 Dec 2025	26 Nov 2025 - 26 Nov 2025
David Shan
Shana Carol Neal
Shana Carol Neal
Roland Goette
Roland Goette
Michael Garrison
Michael Garrison
Michael Feld
Michael Feld
Christopher J. DelOrefice
Christopher J. DelOrefice
Richard Byrd
Richard Byrd
Bilal Muhsin
Thomas E. Polen
Thomas E. Polen
Thomas E. Polen
Pamela L. Spikner
Bertram Lee Scott
Carrie L. Byington
Christopher Ian Montague Jones
Michael Feld
Michael Feld
Claire M. Fraser-Liggett
Claire M. Fraser-Liggett